RACGAP1 pSer387 antibody Ab
- Known as:
- RACGAP1 pSer387 (anti-) Antibody
- Catalog number:
- 1487979
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Acris antibodies
- Gene target:
- RACGAP1 pSer387 antibody
Related genes to: RACGAP1 pSer387 antibody Ab
- Gene:
- RACGAP1 NIH gene
- Name:
- Rac GTPase activating protein 1
- Previous symbol:
- -
- Synonyms:
- MgcRacGAP
- Chromosome:
- 12q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-09
- Date modifiied:
- 2015-08-25
Related products to: RACGAP1 pSer387 antibody Ab
Related articles to: RACGAP1 pSer387 antibody Ab
- Liposarcoma (LPS) is a common soft tissue sarcoma; however, its molecular pathogenesis and immune cell infiltration remain poorly understood. This study investigated potential driver genes and pathways in LPS and characterized immune cell infiltration patterns to identify potential markers for targeted therapy. Differentially expressed genes (DEGs) in LPS were analyzed by GO and KEGG pathway enrichment analysis. A protein-protein interaction network was constructed using the STRING database and visualized with Cytoscape. mRNA expression of genes with high |logFC| values was verified by RT-qPCR. Immune cell subsets were quantified using CIBERSORT. GO and KEGG analysis revealed significant functional clusters and pathways, and most verified genes were consistent with the bioinformatics analysis. Survival analysis showed that high expression of TYMS, KIF20A, BUB1B, LMNB1, RRM2, ZWINT, and RACGAP1 was significantly associated with poor overall survival and poor disease-free survival (DFS). High levels of TMSB15A, TPX2, PKM2, and PTTG1 were significantly associated with poor DFS alone. CIBERSORT analysis identified a significantly higher fraction of resting mast cells (MCs) in LPS tissues compared to normal fatty tissues (P < 0.05). TOP2A, IL-6, PCNA, CDK1, JUN, MYC, CCNB1, EGFR, ACACB, and BIRC5 were identified as potential diagnostic biomarkers of LPS, providing strong evidence for hub gene studies. Immune cell infiltration analysis further suggested that resting MCs may play a potential role in LPS development, although further experimental validation is warranted. Collectively, these findings clarify the molecular basis of LPS and provide a foundation for future research into its treatment. - Source: PubMed
Publication date: 2026/09/11
Liu ChunxiaoWang YanhuaLiu QiuxiaZhang Sha - Hematopoietic stem cells (HSCs) give rise to all blood cell lineages and possess long-term self-renewal potential. HSCs undergo symmetric division for their expansion and asymmetric division to generate one HSC and one progenitor cell that contribute to the production of mature blood cells. The midbody is a structure formed in the center of the intercellular bridge during cytokinesis. However, the midbody is either asymmetrically inherited by one daughter cell or symmetrically released after cell division, whether these distinct patterns of midbody inheritance influence HSC fate remain poorly understood. In this study, we designed a fusion protein humanized monomeric Kusabira-Orange 2 (hmKO2) and male germ cell Rac GTPase-activating protein (MgcRacGAP), which is a component of the midbody. We then traced the midbody inheritance during cell division and the future cell fates of HSC daughters after division by time-lapse imaging. As a result, we found that the midbody release correlated with the delay of the time to the next division but not with the lineage potential of HSCs, indicating the possibility that midbody remnant plays some roles in cell cycle progression. - Source: PubMed
Publication date: 2026/09/06
Fukushima TsuyoshiWehling ArneShimamoto RenAsada ShuheiKawamura ShunsukeFukuyama TomofusaGoyama SusumuSchroeder TimmKitamura ToshioTanaka Yosuke - Glioblastoma (GBM) is the most aggressive primary brain malignancy, characterised by hypoxia-driven proliferation, therapeutic resistance and poor prognosis. While hypoxia-induced transcriptional changes are well documented, the temporal regulation of cell cycle genes under sustained hypoxia remains unclear. - Source: PubMed
Publication date: 2026/07/02
Sharma Manish KChongtham JonitaBhushan AshishChosdol KunzangSinha SubrataSrivastava Tapasya - Cervical cancer continues to pose a considerable challenge to global health, necessitating innovative approaches for improved diagnostics and personalized treatment strategies. Prior investigations have suggested that plasma proteins may play a role in the pathogenesis of cervical cancer; however, these studies do not confirm a causal relationship. To address this gap, conducted a large-scale Mendelian randomization (MR) study of the plasma proteome. - Source: PubMed
Publication date: 2026/07/01
Zhao Yan-HongRuan Qing-FenNing Jing-HuaZhang XinQu RunZou JingLiang YiZhang Cheng-GuiZhang Yu-Zhe - A central objective in oncology is to identify therapeutic targets essential for the survival of proliferating malignant cells. However, a major challenge in pre-clinical research is the scarcity of robust models capable of accurately assessing therapeutic efficacy in patient-specific heterogeneous cancer cells. Here, we developed an ex vivo platform for patient-specific assessment using biomacromolecule-based targeting delivery systems for CRISPR-Cas9 mediated gene knockout and in situ mRNA profiling in patient-derived circulating malignant cells (CMCs). Using a cancer targeting vector, we conducted a personalized evaluation of the impact of Rac GTPase activating protein 1 (RACGAP1) knockout on cell growth in a cancer cell line and patient-derived heterogeneous CMCs. RACGAP1 knockout induced irreversible cytokinesis failure, leading to markedly reduced proliferation and invasion capacity, DNA damage, and increased apoptosis. Our approach establishes a promising strategy for the personalized validation of novel therapeutic targets. - Source: PubMed
Publication date: 2026/06/27
Gao Qing-YuHan DiLiao Xin-RuLei Jin-JuQi Li-JinHuang Qi-YangFu Fei-FeiCheng Si-Xue